Marie-Amélie Ordan1, Camille Mazza1, Coralie Barbe2, Marine Perrier1, Damien Botsen1, Yohann Renard3, Johanna Moreau1, Mathilde Brasseur1,2, Barbara Taillière4, Éric Bertin5, Olivier Bouché1,6. 1. Ambulatory Care Unit, Reims University Hospital, Reims, France. 2. Department of Biostatistics, Reims University Hospital, Reims, France. 3. Department of General and Digestive Surgery, Reims University Hospital, Reims, France. 4. Artificial Nutrition Unit, Reims University Hospital, Reims, France. 5. Department of Nutrition, Endocrinology, and Diabetology, Reims University Hospital, Reims, France. 6. Department of Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France.
Abstract
BACKGROUND: Handgrip strength (HGS) is a widely studied noninvasive test. Weak strength (dynapenia) seems to be associated with high morbidity and mortality in different populations, notably oncology populations. Despite this, HGS testing is not used in daily practice in oncology. The study was aimed at evaluating the feasibility and acceptability of HGS testing in patients with digestive cancer treated with ambulatory chemotherapy. METHODS: In this prospective, single-center study, enrolled patients were followed for 6 months. Two consecutive bilateral measures were performed with a Jamar dynamometer during each patient's appointments in the unit for intravenous treatment. A questionnaire was completed by patients and medical team members. RESULTS: There were 203 consecutive patients, and 201 were recruited. In all, 1704 of 1716 measurements (99.3%) were performed, and 201 patients (99.0%) performed at least 1 measure; 190 (94.5%) performed all expected measures. One hundred sixty-four of 171 participating patients (95.9%) found the test easy to perform, and 167 (97.7%) did not find the test restrictive. All of the 14 medical team members found the test easy to perform, unrestrictive, and undisruptive in their daily practice. CONCLUSIONS: HGS testing is routinely feasible, inexpensive, and well accepted by patients and medical teams in an ambulatory digestive cancer unit. Cancer 2018;124:1501-6.
BACKGROUND: Handgrip strength (HGS) is a widely studied noninvasive test. Weak strength (dynapenia) seems to be associated with high morbidity and mortality in different populations, notably oncology populations. Despite this, HGS testing is not used in daily practice in oncology. The study was aimed at evaluating the feasibility and acceptability of HGS testing in patients with digestive cancer treated with ambulatory chemotherapy. METHODS: In this prospective, single-center study, enrolled patients were followed for 6 months. Two consecutive bilateral measures were performed with a Jamar dynamometer during each patient's appointments in the unit for intravenous treatment. A questionnaire was completed by patients and medical team members. RESULTS: There were 203 consecutive patients, and 201 were recruited. In all, 1704 of 1716 measurements (99.3%) were performed, and 201 patients (99.0%) performed at least 1 measure; 190 (94.5%) performed all expected measures. One hundred sixty-four of 171 participating patients (95.9%) found the test easy to perform, and 167 (97.7%) did not find the test restrictive. All of the 14 medical team members found the test easy to perform, unrestrictive, and undisruptive in their daily practice. CONCLUSIONS: HGS testing is routinely feasible, inexpensive, and well accepted by patients and medical teams in an ambulatory digestive cancer unit. Cancer 2018;124:1501-6.
Authors: An Ngo-Huang; Nathan H Parker; Eduardo Bruera; Rebecca E Lee; Richard Simpson; Daniel P O'Connor; Maria Q B Petzel; Rhodora C Fontillas; Keri Schadler; Lianchun Xiao; Xuemei Wang; David Fogelman; Sunil K Sahai; Jeffrey E Lee; Karen Basen-Engquist; Matthew H G Katz Journal: Integr Cancer Ther Date: 2019 Jan-Dec Impact factor: 3.279
Authors: Marine Perrier; Marie-Amelie Ordan; Coralie Barbe; Camille Mazza; Damien Botsen; Johanna Moreau; Yohann Renard; Mathilde Brasseur; Barbara Tailliere; Philippe Regnault; Eric Bertin; Olivier Bouche Journal: Support Care Cancer Date: 2021-07-12 Impact factor: 3.603